Lecivriens

Levocetirizine, the active ingredient in Lecivriens, is a second‑generation H1‑receptor antagonist presented as an oral tablet for oral use. It relieves symptoms of allergic rhinitis and chronic idiopathic urticaria in adults and adolescents.

GNH USA supplies Lecivriens as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lecivriens, a second‑generation antihistamine, acts on the histamine‑mediated allergic pathway to control a range of IgE‑driven conditions. - Allergic rhinitis: reduces nasal congestion, sneezing, itching and watery discharge. - Chronic idiopathic urticaria: diminishes the number and intensity of hives and associated itching. - Seasonal allergic rhinitis: alleviates symptoms triggered by pollen or other seasonal allergens.

Adverse reactions may occur, ranging from mild to severe. Monitoring for any new symptoms after initiation is recommended.

Common Side Effects: - Drowsiness: mild sedation that may affect alertness. - Headache: transient tension‑type pain. - Dry mouth: reduced salivation. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips or throat requiring urgent care. - Anaphylactic reaction: severe, rapid‑onset allergic response. - Severe skin rash: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before prescribing Lecivriens, clinicians should consider several safety aspects. - Renal impairment: assess function and adjust dose if necessary. - Hepatic impairment: use with caution and monitor liver enzymes. - Elderly patients: observe for increased sedation or dizziness. - Pregnancy: discuss potential risks with a healthcare professional. - Drug interactions: review concomitant medications for possible interactions. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Levocetirizine may interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Ketoconazole: can increase levocetirizine plasma concentrations. - Erythromycin: may raise systemic exposure. - Ritonavir: potential to elevate drug levels significantly.

Moderate Interactions (Monitor Closely): - Alcohol: may enhance drowsiness. - CNS depressants (e.g., benzodiazepines): increased sedation risk. - Theophylline: possible reduction in clearance, requiring observation.